References

IJMABHR

International Journal of Medical and All Body Health Research

IJMABHR

2582-8940

Anfo Publication House

Review: Tocilizumab-A protential drug for Covid-19

Soni

Anjali

Rathore

Aanveekshikee

Gupta

Arun K

1Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India

2021

2 2 06 07 26032021 13042021

CC BY-NC-SA 4.0

Tocilizumab, an interleukin-6 inhibitor, may enhance clinical outcomes by reducing the inflammatory symptoms of severe coronavirus disease 2019 (COVID-19). The reported patients with laboratory-confirmed severe COVID-19 who received tocilizumab and followed up for 14 days were studied retrospectively. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilator support requirements. In this work our aim is to conclude that at what stage tocilizumab is used and what outcomes are observed.

ContraceptionPost placentalIUCD

References 1

Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. International immunopharmacology, 2020, 107018.

Alattar R, Ibrahim TB, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. Journal of medical virology. 2020; 92(10):2042-2049.

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine. 2021; 384(16):1503-1516.

Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Toko L, et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International Journal of Infectious Diseases. 2020; 99:491-495.

Kewan T, Covut F, Al–Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. E Clinical Medicine. 2020; 24:100418.

Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases. 2021; 73(2):e445-e454.

Dewi IM, Janssen NA, Rosati D, Bruno M, Netea MG, Brüggemann RJ, et al. Invasive pulmonary aspergillosis associated with viral pneumonitis. Current Opinion in Microbiology. 2021; 62:21-27.

Kotak S, Khatri M, Malik M, Malik M, Hassan W, Amjad A, et al. Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence. Cureus, 2020, 12(10).

Huang E, Isonaka S, Yang H, Salce E, Rosales E, Jordan SC. Tocilizumab treatment in critically ill patients with Covid-19: A retrospective observational study. International Journal of Infectious Diseases. 2021; 105:245-251.

Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe Covid-19. Scientific reports. 2020; 10(1):1-7.

Vu CA, DeRonde KJ, Vega AD, Maxam M, Holt G, Natori Y, Zamora JG, et al. Effects of Tocilizumab in COVID-19 patients: a cohort study. BMC infectious diseases. 2020; 20(1):1-10.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: a single center experience. Journal of medical virology. 2020; 92(7):814-818.

Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19. Journal of translational medicine. 2020; 18(1):1-5.

Kaye AG, Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe Covid-19 mortality: A systematic review. Peer J. 2020; 8:p.e10322